Physician profile
Chad Michael Blunt
NPI 1447345301
$7,686.32
in general payments reported to CMS, 2019-2025
38 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2020: $829 · 2021: $1,675 · 2022: $1,271 · 2023: $868 · 2024: $1,040 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $977.93 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $738.82 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $736.28 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.63 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $598.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $386.77 | 2019-2024 | Otezla, Repatha, Evenity |
| Pfizer INC. | $378.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $246.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $235.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $203.87 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.48 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $195.69 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.87 | 2019-2023 | Gattex |
| Kowa Pharmaceuticals America, INC. | $182.81 | 2019-2023 | Seglentis, Livalo |
| Biohaven Pharmaceuticals, INC. | $179.69 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Blunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.